Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Poolbeg Pharma Ltd. (GB:POLB)
LSE:POLB
RESEARCH TOOLSreports
Holding GB:POLB?
Track your performance easily
POLB Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range7.05p - 15.77p
Previous Close7.9p
Volume1.61M
Average Volume (3M)1.10M
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)£2.26M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Feb 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding500,000,000
10 Day Avg. Volume994,027
30 Day Avg. Volume1,100,173
Standard Deviation0.18
R-Squared0.23
Alpha-0.00577
Financial Highlights & Ratios
Price to Book (P/B)380.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Poolbeg Pharma Ltd. News
PremiumCompany Announcements
Poolbeg Pharma Enhances IP Portfolio with US Patent
PremiumCompany Announcements
Poolbeg Pharma to Unveil Promising POLB 001 Data
PremiumCompany Announcements
Poolbeg Pharma Advances Promising TherapiesPremiumCompany Announcements
Poolbeg Pharma to Showcase at Global Investment Conference
PremiumCompany Announcements
Poolbeg Pharma Sees Major Voting Rights ShiftPremiumCompany Announcements
Poolbeg Pharma to Withdraw from OTCQB Market
PremiumCompany Announcements
Poolbeg Pharma Investor’s Voting Rights Surge
PremiumCompany Announcements
Poolbeg Pharma Announces New London AddressOptions Prices
Currently, No data available
---
Ownership Overview
POLB FAQ
What was Poolbeg Pharma Ltd.’s price range in the past 12 months?
Poolbeg Pharma Ltd. lowest share price was 7.05p and its highest was 15.77p in the past 12 months.
What is Poolbeg Pharma Ltd.’s market cap?
Currently, no data Available
When is Poolbeg Pharma Ltd.’s upcoming earnings report date?
Poolbeg Pharma Ltd.’s upcoming earnings report date is Feb 27, 2025 which is in 96 days.
How were Poolbeg Pharma Ltd.’s earnings last quarter?
Poolbeg Pharma Ltd. released its earnings results on Sep 18, 2024. The company reported -0.004p earnings per share for the quarter, the consensus estimate of -0.004p by 0p.
Is Poolbeg Pharma Ltd. overvalued?
According to Wall Street analysts Poolbeg Pharma Ltd.’s price is currently Overvalued.
Does Poolbeg Pharma Ltd. pay dividends?
Poolbeg Pharma Ltd. does not currently pay dividends.
What is Poolbeg Pharma Ltd.’s EPS estimate?
Poolbeg Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Poolbeg Pharma Ltd. have?
Poolbeg Pharma Ltd. has 500,000,000 shares outstanding.
What happened to Poolbeg Pharma Ltd.’s price movement after its last earnings report?
Poolbeg Pharma Ltd. reported an EPS of -0.004p in its last earnings report, expectations of -0.004p. Following the earnings report the stock price went up 3.061%.
Which hedge fund is a major shareholder of Poolbeg Pharma Ltd.?
Currently, no hedge funds are holding shares in GB:POLB
---
Poolbeg Pharma Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
GB:POLB Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.05%
12-Months-Change
Fundamentals
Return on Equity
-30.18%
Trailing 12-Months
Asset Growth
-23.78%
Trailing 12-Months
Company Description
Poolbeg Pharma Ltd.
Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables us to develop multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for Big Pharma seeking mid-stage products to license or acquire.
---
Technical Analysis
---